The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses

M.C. Jones, Keith Nicol Stewart, D J PROPPER, G.R.D Catto, D A POWER

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Antigen pre-treatment in animals undoubtedly prolongs graft survival. In man, however, routine pre-transplantation blood transfusions have recently become controversial, principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates. We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies. A total of 24 patients were recruited to the study; ten received cyclosporin with blood transfusions (BT) (group 1), 14 received BT alone (group 2). Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 (P < 0.05). Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 (P < 0.006) The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalNephrology Dialysis Transplantation
Volume6
Issue number2
Publication statusPublished - 1991

Keywords

  • CYCLOSPORINE
  • ALLOANTIBODIES
  • ANTIIDIOTYPIC ANTIBODIES
  • SENSITIZATION
  • RENAL-ALLOGRAFT RECIPIENTS
  • DONOR-SPECIFIC TRANSFUSION
  • TRANSPLANT RECIPIENTS
  • BROAD SENSITIZATION
  • KIDNEY-TRANSPLANTS
  • GRAFT-SURVIVAL
  • CROSSMATCH
  • RELEVANCE
  • ASSAY

Fingerprint

Dive into the research topics of 'The Effect of Cyclosporine Administered During a 3rd-Party Blood-Transfusion Protocol on Humoral Immune-Responses'. Together they form a unique fingerprint.

Cite this